Latest news with #GastroesophagealRefluxDisease
Mint
4 days ago
- Business
- Mint
Mankind to expand gastro, derma presence, says MD Rajeev Juneja
Mankind Pharma is focused on expanding its presence in the gastrointestinal and dermatology segments this year, as it looks at expanding its presence in the chronic segments, managing director Rajeev Juneja toldMintin an interview. 'We are not great in the gastro [segment]...we have decided that we are supposed to work a lot in gastro because it has become semi-chronic, and our inclination is towards the chronic side," Juneja said, adding thatgastro in India is one of the fastest-growing segments. 'Along with this, we are working on derma as well," he said. The gastro segment grew 7.3% year on year in April, according to pharma intelligence platform Pharmarack. Further, Mankind is developing a novel anti-obesity and diabetes drug in-house. The drug candidate, GRP119, is currently in phase 2 trials in Australia, and Juneja said that results are expected in the next six to nine months. In FY25, Mankind signed a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialise its novel drug Vonoprazan, to treat Gastroesophageal Reflux Disease (GERD). Also Read: Sun Pharma to ramp up growth-boosting specialty portfolio in FY26 Juneja said that the company is evaluating all options to increase its presence in these therapy areas, including in-licensing products from innovators or small acquisitions. 'No past strategy can be guaranteed for future success. So we need to apply our mind and try to bring some kind of differentiation in whatever we do," said Juneja. 'The point is that once we decide that our intention is that we are supposed to be good on the gastro side, we start searching for avenues, we start searching for people, we start searching for products," he said. The company will also continue to strengthen its leadership in the women's health segment, which received a boost last year through its acquisition of Bharat Serum and Vaccines (BSV). With its foundation strengthened in FY25, Mankind aims to grow 1.2 to 1.3 times the Indian pharmaceutical market. Juneja said this will be driven by its focus on its chronic domestic formulations portfolio. Juneja said the focus is also on growing larger brands, from the current ₹50 crore to ₹100 crore brands for products to ₹500 crore brands. 'This is the strategy we basically want to pursue in future, because we have seen that once you create that kind of a brand, that's a very big entry barrier," he added. BSV acquisition Mankind is on track with the integration of BSV, which it acquired for ₹13,768 crore in October 2024. The integration will be funded through a mix of internal accruals and external debt. Juneja said the company focused on removing the 'extra flab" and bringing in the right talent for the acquired entity in FY25. This year, he expects 18-20% growth from the BSV portfolio. The goal is to increase the reach and awareness of BSV's niche super-speciality products. BSV is working on two biosimilars, the company's investor presentation highlighted, although Juneja declined to share more details on the BSV pipeline. Also Read: Emcure Pharmaceuticals to expand gynaecology, derma portfolio for India market in FY26 Vishal Manchanda, senior vice president of Institutional Equities at Systematix Group, toldMintthat BSV's platform and skillset for making recombinant drugs (created by inserting genes from one species into a host species) can be leveraged to make biosimilars. Select companies in India, including Biocon, are skilled at the recombinant process. However, Manchanda pointed out that Mankind has the potential to scale this up meaningfully. Innovation push 'If you're a pharma company, naturally, you gain respect once you have great R&D," Juneja said. 'We started our own R&D in Mankind 13-14 years back…going forward, we'll be putting a bit more money in the R&D side…our R&D expenses will increase because that would be the future need as well." 'We wish to become a bigger company…our dream is to become India's number one company on the domestic side," Juneja said, adding that 'we need to have certain innovative products, and we are working for that". Mankind's focus on innovation and speciality segments comes as the Indian pharmaceutical market has become more crowded. Most segments already have established market leaders. '…the promoters are realising that there is a challenge to growth. And they know the space they have been playing in is now kind of difficult to expand from where they are, meaningfully expand from where they are. So I think Mankind promoters being extremely committed to India business, they are also kind of prepared on how to take this forward," Manchanda said. 'What they are actually looking for is a bigger avenue to build growth on," he added, referring to Mankind's BSV acquisition. Internal corrections Mankind undertook several internal correction initiatives in the last year, including leadership changes and improving synergies between its divisions, Juneja said. Also Read: Zydus bets big on vaccines and medtech 'If you look at the history of Mankind, in 30 years, we have become the fourth largest company," Juneja said, adding that for any company growing very fast, there comes a time when growth plateaus. 'But once you bring commercial excellence, you bring people from outside…a number of flaws can come in front of you, and you have two choices: Either to remove those flaws gradually without affecting your sales and profit and growth, or second, do it immediately," Juneja said. 'We belong to the second category, and we decided that by March 2025, we'll clean up Mankind from every side," he added.
NDTV
23-05-2025
- Health
- NDTV
Should You Consider Taking Antacids For The Long Run?
Antacids are among the most commonly used over-the-counter medications to relieve heartburn, indigestion, and acid reflux. They offer quick relief by neutralising stomach acid, making them a go-to remedy for millions. But while they are effective in the short term, long-term use of antacids is a growing concern among healthcare professionals. According to the American Gastroenterological Association (AGA), prolonged use of antacids, especially without medical supervision, can lead to nutrient deficiencies, altered gut function, and increased risk of kidney and bone issues. So, should you consider taking antacids for the long haul? Let's explore the science behind long-term use and what you should watch out for. Understanding how antacids work and their implications Antacids work by neutralising excess stomach acid, offering temporary relief from symptoms like heartburn and bloating. However, they don't treat the root cause of acid reflux or indigestion, and prolonged use can suppress natural digestive functions. Here are some key concerns and complications linked to continuous or unsupervised use of antacids. 1. Nutrient deficiencies Long-term use of antacids, especially proton pump inhibitors (PPIs), can hinder the absorption of essential nutrients such as the following mentioned below. The National Institutes of Health (NIH) warns that prolonged PPI use has been linked with osteoporosis-related fractures. a. Vitamin B12 Low stomach acid affects absorption, increasing the risk of anaemia and neurological issues. b. Calcium and magnesium Reduced absorption can lead to weaker bones and muscle cramps. c. Iron Essential for haemoglobin, iron levels may drop over time, leading to fatigue and weakness. 2. Risk of kidney problems Some studies suggest that long-term antacid use may be associated with an increased risk of chronic kidney disease. PPIs in particular have been shown to potentially cause the risk of following health conditions. It is advisable to undergo periodic kidney function tests if you're using antacids regularly. a. Damage kidney tissues b. Contribute to the development of interstitial nephritis c. Lead to long-term renal impairment if left unmanaged 3. Increased risk of infections By suppressing stomach acid, long-term antacid use may reduce the stomach's natural defence mechanism, allowing harmful bacteria to flourish. The Centres for Disease Control and Prevention (CDC) states that reducing stomach acid can compromise your gut's immune function. This may include the following health risks. a. Increase the risk of Clostridium difficile infections b. Lead to bacterial overgrowth in the gut c. Make one more prone to gastrointestinal issues like diarrhoea 4. Masking of underlying conditions Relying on antacids for too long can mask more serious gastrointestinal disorders such as the following. If symptoms like heartburn, bloating, or nausea persist for weeks, a proper medical evaluation is crucial. a. Gastroesophageal Reflux Disease (GERD) b. Peptic ulcers c. Helicobacter pylori infection d. Stomach cancer 5. Rebound acidity When stopped suddenly after long-term use, especially with PPIs, the stomach may produce even more acid than before, a phenomenon known as rebound hyperacidity. This can worsen symptoms and create a dependency loop on antacids. When and how to use antacids safely If you need antacids occasionally, they are generally safe. However, for long-term relief, consider the following. Also, consider alternatives like H2 blockers, only under professional guidance. a. Consulting a gastroenterologist before prolonged use b. Exploring dietary and lifestyle changes to manage symptoms c. Using the lowest effective dose under supervision d. Regularly monitoring nutrient levels and kidney function While antacids are a convenient solution for occasional discomfort, they aren't designed for long-term use without medical advice. Prolonged use can lead to serious health complications and mask underlying conditions. According to the World Health Organisation (WHO) and leading gastroenterologists, it's best to address the root cause of acidity through medical care, lifestyle changes, and proper dietary habits for long-term wellness. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
Khaleej Times
20-05-2025
- Health
- Khaleej Times
Over 30% UAE residents have acid reflux; untreated cases may lead to cancer, say doctors
More than 30 per cent of UAE residents suffer from acid reflux, a common digestive issue that can progress to Gastroesophageal Reflux Disease (GERD). However, this common issue risks developing into something more serious and regular check-ups and timely intervention are crucial. Doctors in the UAE are raising awareness about the condition, especially for patients with persistent or long-standing reflux. While often manageable, GERD carries the risk of developing into Barrett's oesophagus — a condition linked to an increased chance of oesophageal cancer. Michael Anthony John Caselberg, a 53-year-old British man, sought medical help after experiencing altered bowel habits, chest discomfort, and severe acid reflux. His diagnosis was serious and complex: moderate inflammation of the oesophagus caused by acid reflux (Grade B Reflux Esophagitis), a large hiatus hernia, Barrett's oesophagus, erosive gastroduodenitis, and multiple colonic polyps. "These conditions are rare and can lead to serious complications, especially the potential for cancer in the case of Barrett's oesophagus,' his attending doctor noted. Large hiatus hernias, like the one Caselberg has, occur in less than five per cent of hernia cases. Meanwhile, Barrett's oesophagus is found in about 1–2 per cent of people with chronic GERD. Medical experts weigh in Dr Sandeep Patil, specialist general surgery at Aster Cedars Hospital and Clinic in Jebel Ali, emphasised the benefits of surgical treatment. 'Laparoscopic fundoplication is a highly effective and minimally invasive technique for addressing large hiatus hernias and severe acid reflux. The procedure's high success rate globally — ranging from 90–95 per cent — is a testament to its effectiveness.' Explaining how GERD leads to Barrett's oesophagus, Dr Akhilesh Sapra, specialist gastrointestinal surgeon at Prime Hospital, said, 'GERD is a chronic digestive disorder where stomach acid or bile flows back (refluxes) into the oesophagus, irritating its lining. This backward flow occurs due to weakness or relaxation of the lower oesophageal sphincter (LES) — a muscular valve that normally keeps stomach contents from coming back up.' He explained how the body reacts to this damage over time. 'Chronic GERD means that stomach acid keeps coming up into the oesophagus over a long time. This acid irritates and damages the lining of the oesophagus. To protect itself, the body changes the normal cells in that area into a different type—ones that can handle the acid better. This change in the cells is called Barrett's oesophagus. While it's the body's way of coping, these new cells are not normal for the oesophagus and can sometimes turn into cancer over time.' Early detection is key Dr Najeeb Salah Abdulrahman, Specialist Gastroenterologist at International Modern Hospital Dubai, emphasised the importance of vigilance. 'What's crucial is early detection and regular surveillance. If caught early, treatment options like endoscopic ablation can prevent progression to cancer. Patients should also focus on long-term GERD management through lifestyle modifications, acid suppression therapy, and avoiding smoking or obesity — all of which are known risk factors.' He warned that symptoms aren't always obvious. 'Many patients may not have noticeable symptoms, which is why individuals with long-standing GERD (especially more than five years) should undergo screening endoscopy.' Understanding the cancer risk Dr Mahroos Al Rejjal, Specialist Gastroenterology at Saudi German Hospital in Ajman, provided some perspective on the cancer risk: 'The cancer risk for patients with no dysplastic Barrett's oesophagus was approximately 0.5 per cent per year. However, more recent studies suggested that the cancer risk for such patients is even lower, in the range of only 0.12 per cent to 0.33 per cent per year.' Still, doctors agree that regular check-ups and timely intervention are crucial to reducing risk and improving patient outcomes. Common warning signs include persistent heartburn, difficulty swallowing, a sensation of food sticking in the chest, and chronic cough or hoarseness — though not everyone experiences symptoms.
Indian Express
07-05-2025
- Health
- Indian Express
A peanut got stuck in 3-year-old's windpipe: Why are children prone to swallowing and feeding difficulties?
When a three-year-old girl was brought into the emergency room of Max Hospital, Shalimar Bagh, Delhi, in a critical condition with high-grade fever, cough, vomitting bouts and severe respiratory distress, her parents thought she had contracted some serious infection. But paediatric pulmonologist Dr Deepak Kumar suspected that something had gone into her windpipe. Tests showed fragments of a peanut she had eaten 10 days ago. Putting his stethoscope on her heaving chest, he noticed that there was poor air flow on the right side of her chest and a wheezing sound. A chest X-ray confirmed his suspicion of a foreign body trapped in the child's airways. He performed a bronchoscopy in the paediatric intensive care unit as the camera-mounted wire hit the peanut lodged in the right main bronchus (one of the main tubes that carry air to the lungs). He manoeuvred it to remove the nut fragments, restoring the child's ability to breathe normally in four hours and sparing her from potentially life-threatening complications. 'Some tissue had also formed around the peanut due to the body's inflammatory response. With steroids for inhalation, she recovered completely,' says Dr Kumar. What are common food items that put children at risk? Dr Sonia Mittal, Director, Paediatrics, who has seen many such cases of foreign objects getting stuck in children's windpipes, says parents should watch over hard solids in their children's diet. 'Peanuts, dry fruits, candies, small toys, beads and marbles are often swallowed by kids. Organic materials like peanuts can cause significant inflammation in the airways if not removed promptly. This can lead to severe complications if not diagnosed early. In this case, timely identification, diagnostics and intervention ensured the child's complete recovery. The peanut was stuck for at least 10 days,' she says. Why does food get into children's windpipe often? Food can enter a toddler's windpipe (trachea) during swallowing due to a condition called aspiration. Children under the age of three are still learning how to eat properly. 'In the body, there are two main pipes — the windpipe (trachea) and the esophagus (food pipe). When we swallow food, a flap called the epiglottis partially covers the windpipe to prevent food from entering it, allowing us to breathe safely. However, young children often play or run while eating and if they eat solid food during this time, it can accidentally slip into the windpipe instead of going down the esophagus. This isn't a disease — it's typically an accidental occurrence,' says Dr Kumar. The only medical conditions where the child can have trouble swallowing are when they have a development disorder like a cleft palate or a problem in the oesophagus, neuromuscular disease, cerebral palsy or Gastroesophageal Reflux Disease (GERD). What should be the feeding protocol? Parents should powder and crush nuts and other solid foods to minimise the risk of choking in children under three years of age. Change the thickness of liquids too.
